Site Editors

Shaji K. Kumar, MD

Prashant Kapoor, MD, FACP


Comparing Infections Rates With Bispecific Antibodies in Relapsed or Refractory Multiple Myeloma

By: Joshua D. Madera, MD
Posted: Tuesday, January 2, 2024

Despite the therapeutic benefits of treatment with bispecific antibodies for patients with relapsed or refractory multiple myeloma, infections remain a concern, according to the results of a French study presented at the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition (Abstract 1005). In fact, patients treated with anti–B-cell maturation antigen (BCMA) bispecific antibodies may be more susceptible to infectious complications than those treated with anti-G protein–coupled receptor, class C, group 5, member D (GPRC5D) bispecific antibodies, suggested Aurore Perrot, MD, PhD, of Université de Toulouse, France, and colleagues.

From 2020 to 2023, a total of 229 patients with relapsed or refractory multiple myeloma were retrospectively assessed. Patients were stratified based on their treatment with anti-BCMA bispecific antibodies such as teclistamab-cqyv (n = 153), anti-BCMA bispecific antibodies such as elranatamab-bcmm (n = 47), or anti-GPRC5D bispecific antibodies such as talquetamab-tgvs (n = 29). The clinical status of these patients was monitored regularly to assess for infections, hospitalizations, and delays in treatment.

A total of 142 patients were revealed to have experienced a sum of 234 infectious events. The most severe grade 4 or higher infections occurred in patients treated with anti-BCMA bispecific antibodies (20.6%). Most infections were either localized to the pulmonary tract (41%) or disseminated (22%). In addition, infections were primarily bacterial (55%), although viral (39%) and fungal (5%) infections were also reported. Moreover, 57% of patients were hospitalized, with 13% requiring intensive care. Furthermore, the global cumulative incidence rates of first infection were 73% in patients treated with anti-BCMA bispecific antibodies and 51% in those treated with anti-GPRC5D bispecific antibodies.

Disclosure: For full disclosures of the study authors, visit

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.